Cervical cancer is preventable because it has an established etiology, mainly attributed to a detectable pathogen, human papillomavirus (HPV). In 2018, the world health organization issued an unprecedented call for global action to eliminate cervical cancer by 2030. The adaptation of regular screening programs is fundamental to achieve the goal of cervical cancer elimination. However, it is still difficult to achieve satisfactory coverage rates of screening in developing countries as well as in developed countries because many women are reluctant to participate in gynecologic examination. HPV detection in urine is a convenient, widely acceptable by women and relatively affordable without the necessity for clinical visits to improve the coverage rates of cervical cancer screening. Unfortunately, the clinical implementation of urine-based tests for HPV detection has been hindered by the lack of standardized tests. Further optimization of protocols and standardization of urinary HPV detection are expected to be realized. With the advantages of urine sampling to overcome cost, personal, and cultural barriers, time has come for the standardized tests to facilitate a wide clinical implementation of urinary HPV detection that will significantly contribute to the WHO's goal, that is, to eliminate the cervical cancer globally.

Les premiers cas d'infection dus à un nouveau Coronavirus, le SARS-CoV-2 ont été enregistrés en Chine en décembre 2019. Cette maladie, désormais appelée COVID-19, a été déclarée comme pandémie par l'Organisation Mondiale de la Santé (OMS) trois mois après soit en mars 2020. Le plus souvent à l´origine d´un syndrome infectieux sans gravité, associant à différents degrés des symptômes bénins (fièvre, toux, myalgies, céphalées et éventuels troubles digestifs). Le SARS-CoV-2 peut être à l´origine de pathologies pulmonaires graves et parfois de décès. Les données sur les conséquences pendant la grossesse sont limitées. À l'heure actuelle, les données concernant l'infection par SARS-CoV-2 sont rassurantes et n'indiquent pas un nombre d'infection plus élevé ni un risque surajouté de complications chez la femme enceinte par rapport à la population générale. Quelques exceptionnels cas de mortalité maternelle existent, mais surviennent le plus souvent sur des terrains qui présentent d'autres pathologies, particulièrement la pré-éclampsie. L´objectif de notre travail est de rapporter les données cliniques, biologiques et évolutives materno-fœtales, à travers une étude rétrospective au sein de l´Hôpital Militaire Marocain COVID-19 de Benslimane, s´étalant sur une période de 3 mois allant du 21 juillet au 21 octobre 2020.

No abstract

Minimally invasive gynecologic surgery such as hysteroscopy has a low risk of complications. Infections, however, are more common in the presence of risk factors such as smoking, history of pelvic inflammatory disease, and endometriosis. We report the case of a patient who underwent operative hysteroscopy without immediate complications and was admitted 2 days later to the emergency department in a severe state of septic shock. With multiple organ failures requiring admission to an intensive care unit, the patient died despite extensive antibiotic therapy and vasoactive drugs. Ascending infection can be a potentially fatal complication of hysteroscopy, even in the absence of known risk factors.

The stomach is one of the frequent sites of metastasis from invasive lobular carcinoma of the breast. The clinical presentation and the endoscopic findings for metastasis carcinoma are nonspecific and may mimic that of a primary gastric tumor. The distinction between these two neoplasms may be very difficult but essential as the basis of the treatment is different. Histological and immunohistochemical analyses are the gold standard for establishing the diagnosis of the primary site. We report the case of a 68-yearold patient with metastatic breast cancer mimicking a primary stomach cancer.